deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00321685

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Rectal Adenocarcinoma Stage II Rectal Cancer AJCC v7 Stage III Rectal Cancer AJCC v7
Interventions Bevacizumab Capecitabine Fluorouracil Leucovorin Calcium Oxaliplatin Radiation Therapy Therapeutic Conventional Surgery
Updated 16 times since 2017 Last updated: Mar 13, 2019 Started: Jul 25, 2006 Primary completion: Aug 12, 2013 Completion: Feb 11, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Rectal Adenocarcinoma and Stage II Rectal Cancer AJCC v7, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 16 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2019 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  7. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Sep 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  9. Jul 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Allentown, United States , Atlanta, United States , Aurora, United States , Barberton, United States , Bellefontaine, United States , Berwyn, United States , Bettendorf, United States , Birmingham, United States , Burnsville, United States and 58 more locations